Views & Analysis UK life sciences: the impact of a cycle of affordability and... The changing landscape for drug pricing and some pointers for the UK life sciences sector.
News NHS funding for five MS drugs under threat NICE calls for further discounts on beta-interferons and Copaxone
Views & Analysis The honest broker in market access Eric Low shares his views on why hurdles remain to new drug access.
News Pfizer's Ibrance available across UK after thumbs up in Scot... Around 800 women have received the drug for free.
News NICE recommends Eisai's kidney cancer combination NICE has recommended Eisai’s Kisplyx (lenvatinib) in combination with Novartis’ Afinitor (everolimus) in kidney cancer after the company further dropped its price.
Views & Analysis Real-world data – optimising your strategy for market access... The points to consider in preparing an effective data strategy.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
